BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tuvutromstat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tuvutromstat\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04794699-2040@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:Tuvutromstat: Phase 1 readout est. (NCT04794699)
DESCRIPTION:Tuvutromstat\, phase 1.\nStudy: Study of IDE397 in Participants
  With Solid Tumors Harboring MTAP Deletion\nEstimated primary completion: 
 7 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tuvut
 romstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04794699
URL:https://assetmemo.bio/drug/tuvutromstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277413-2040@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tuvutromstat: Phase 1 readout est. (NCT07277413)
DESCRIPTION:Tuvutromstat\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced So
 lid Tumors\nEstimated primary completion: 30 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tuvutromstat#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07277413
URL:https://assetmemo.bio/drug/tuvutromstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
